🇪🇺EU · EMAAuthorisedATC: A10AE04

Abasaglar (previously Abasria)(insulin glargine)

Diabetes Mellitus

Marketing Authorisation Holder: Eli Lilly Nederland B.V.

EMA Authorisation: 09/09/2014

INN: insulin glargine

Indication

Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Abasaglar (previously Abasria) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Abasaglar (previously Abasria)Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.